本轮融资的完成，标志着资本市场对空山慈科技技术壁垒与临床价值的高度认可。本轮融资后，团队将 加速技术迭代与临床转化，持续构筑核心壁垒。 未来，公司将继续深耕脑机交互与神经调控领域，致力于成为全球领先的脑科学智能基础设施平台，推 动前沿技术从实验室走向临床、走进家庭。 近日，专注无创脑机接口与神经调控的上海空山慈科技有限公司（下称"空山慈科技"）宣布完成Pre-A 轮融资。本轮融资由云启资本独家领投，所募资金将主要用于核心技术研发、临床转化及全球化拓展。 ...

Core Viewpoint - Neurent Medical has completed a $74 million (approximately 510 million RMB) Series C financing, marking a transition from the "technology validation phase" to the "clinical penetration phase" following FDA 510(k) approval of its Neuromark system in 2025 [1][2]. Financing and Use of Funds - The funds will primarily be used for three areas: promoting the Neuromark system, building real-world evidence through multi-center studies, and developing new indications and product iterations [2][5]. Technology and Mechanism - Chronic rhinitis is increasingly recognized as driven by abnormal excitation of the parasympathetic nervous system rather than solely an inflammatory disease [3]. - Neuromark focuses on "functional regulation" by precisely adjusting nerve activity rather than tissue removal, addressing limitations of traditional treatment methods [4]. Engineering Design and Operation - Neuromark is an impedance-controlled radiofrequency nerve modulation system characterized by "precise positioning + controlled energy + real-time feedback" [8]. - The system features a flexible catheter design that can access narrow areas of the nasal cavity, ensuring stable contact with nerve distribution [9]. - It employs real-time impedance measurement to adjust radiofrequency power and duration, aiming to alter nerve conduction rather than burn tissue, thus reducing mucosal necrosis and postoperative pain [10]. Clinical Value and Target Population - Typical patients include those with long-term medication dependence and recurrent symptoms, with studies showing sustained symptom score reductions for over a year and potential for reduced long-term medication use [11][12]. Company Background - Neurent Medical, based in Ireland, focuses exclusively on nasal nerve modulation, differing from traditional ENT companies by establishing a comprehensive treatment pathway around a single disease [13][14]. - The development logic follows a path of accumulating evidence for a single indication, leading to guideline inclusion and payment negotiations [15]. Significance of Financing - The financing is crucial for supporting physician training and real-world data collection, which are key for integrating nerve modulation products into healthcare reimbursement systems [16]. Conclusion - For chronic rhinitis, a high-prevalence condition often managed with medication, the clinical breakthrough is expected to come from the establishment of repeatable and standardized treatment methods rather than singular technological advancements [17].

Core Insights - Neurotechnology is transitioning from basic research to clinical application and industrialization, driven by the increasing burden of neurological diseases, rapid breakthroughs in brain science, and the deep integration of engineering technology and computational capabilities [1] - The first Global NeuroTech Conference 2026 will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect brain science research, engineering technology, clinical applications, corporate innovation, capital, and regulation [1] - The conference will feature the release of the "2026 Global Neurotechnology Innovation White Paper," which will focus on various key areas including brain-computer interfaces, neural modulation technologies, and AI in computational neuroscience [2] Section Summaries Section 1: White Paper Release - The conference will officially release the "2026 Global Neurotechnology Innovation White Paper," focusing on areas such as brain-computer interfaces (BCI), neural modulation technologies (DBS, TMS, VNS, SCS), neuroimaging, and clinical translation paths for neurotechnology [2] Section 2: Innovation Awards - Multiple annual awards will be presented at the conference, evaluating innovations in neurotechnology based on originality, clinical potential, industrial value, and long-term development capabilities, emphasizing collaborative innovation between foundational breakthroughs and engineering realizations [3] Section 3: Thematic Forums - The forums will cover cutting-edge topics in neurotechnology, including brain-computer interfaces, neural modulation technologies, neuroimaging, AI in neuroscience, and discussions on the ethical and commercial pathways for neurotechnology [4] Audience Composition - The conference will target a diverse audience, including neurotechnology companies, clinical experts, researchers, investors, and regulatory professionals, emphasizing a forward-looking and research-oriented approach [8][10] Sponsorship Opportunities - The conference offers sponsorship opportunities for neurotechnology enterprises and institutions, ensuring compliance and sustainable collaboration while maintaining academic rigor and industry depth [7] Conference Details - The conference is expected to host around 800 participants, providing a platform for showcasing cutting-edge technologies and fostering connections between research, clinical, and engineering resources [9]

Core Insights - The brain-computer interface (BCI) sector is experiencing significant investment and government support, marking a transition from experimental technology to industrial application [2][19] - A notable case involves an 11-year-old boy who, after a severe spinal injury, underwent innovative rehabilitation combining spinal cord stimulation and exoskeleton technology, leading to remarkable recovery [4][6] Investment and Government Support - Leading company Strong Brain Technology secured approximately 2 billion yuan in funding, setting a record for non-invasive BCI financing [2] - Various provinces, including Beijing and Guangdong, are incorporating BCI into their government work reports, indicating strategic national interest [2] Technological Advancements - The integration of BCI and spinal cord stimulation technologies is reshaping rehabilitation approaches, with significant improvements in patient outcomes [3][5] - The development of adaptive filtering algorithms has enhanced the accuracy of muscle signal detection, crucial for effective treatment [5] Clinical Applications and Challenges - The case of the boy illustrates the potential of BCI technology in clinical settings, showcasing a successful transition from laboratory research to practical application [6][8] - The complexity of spinal cord injuries necessitates personalized treatment plans, as patient responses can vary widely based on numerous factors [14][15] Regulatory Landscape - Recent guidelines from the National Medical Products Administration aim to clarify the registration process for BCI devices, though strict definitions have sparked debate within the industry [17][18] - The dual nature of invasive and non-invasive BCIs presents regulatory challenges, particularly concerning safety and ethical considerations [18] Future Outlook - The BCI industry is poised for growth, with projections indicating significant breakthroughs and commercialization by 2027 [19][22] - The convergence of AI and BCI technologies is expected to enhance signal decoding and treatment efficacy, potentially revolutionizing rehabilitation practices [20][21]

Core Insights - Boston Scientific has completed the acquisition of Nalu Medical for approximately $600 million in cash, which includes the purchase of remaining shares after previously holding a strategic investment since 2017 [2][6] - Nalu Medical specializes in spinal and peripheral nerve stimulation technologies aimed at chronic neuropathic pain patients, utilizing low-intensity electrical pulses to modulate pain signals before they reach the brain [5][6] - The acquisition is part of Boston Scientific's broader strategy to enhance its portfolio in interventional therapy and pain management, following a series of significant acquisitions in recent years [7][9] Nalu Medical's Product Technology and Business Expectations - Nalu's peripheral nerve stimulation system received FDA approval in 2019 and was further approved for full-body MRI scans in 2025, indicating regulatory progress [6] - The company introduced a miniaturized wearable external power source and completed a $50 million growth funding round in 2025 [6] - Nalu is expected to generate over $60 million in revenue in 2025, with a projected year-on-year growth of over 25% in 2026 [6] Financial Impact and Strategic Positioning - The acquisition is anticipated to have a minimal impact on adjusted earnings per share in 2026, with a gradual positive effect starting in 2027, although there may be short-term dilution on GAAP earnings due to amortization and acquisition-related expenses [6] - Boston Scientific's recent acquisitions, including a $14.5 billion deal for Penumbra and others, reflect a strategic focus on expanding capabilities in interventional treatment and nerve modulation [7][11] Industry Background - The acquisition of Nalu Medical aligns with Boston Scientific's ongoing efforts to strengthen its position in the chronic pain treatment and minimally invasive intervention sectors, which are critical areas of development in the medical technology industry [9][13] - Nalu's innovative features, such as a battery-free micro-implantable pulse generator and smartphone-based treatment control, highlight advancements in pain management technology [10]

Summary of Aipeng Medical Conference Call Company Overview - Aipeng Medical focuses on the commercialization of non-invasive brain-computer interfaces, particularly in intraoperative anesthesia monitoring, achieving over 10 million yuan in revenue. However, progress has been hindered by medical cost control measures, prompting the company to actively explore new applications [2][6]. Key Points and Arguments Revenue Projections - The company anticipates that new applications targeting treatment systems for refractory insomnia and multimodal ADHD could generate tens of millions of yuan in revenue by 2026, with 2027 potentially marking a turning point in performance, contingent on a solid commercialization foundation in hospitals [2][6]. Product Offerings and Market Penetration - Aipeng Medical's perioperative brain state monitoring product is available in approximately 20 provinces, charging around 300 yuan per session, and is not covered by medical insurance. Similar models are used for the refractory insomnia and pediatric ADHD treatment systems [2][7]. - The intraoperative anesthesia monitoring product has been adopted in over 100 hospitals, with a target of exceeding 200 by 2026. The refractory insomnia treatment system has partnered with two hospitals, while the pediatric ADHD treatment aims to cover the top 100 pediatric clinics in China [2][8]. Research and Development - A semi-invasive epilepsy warning product is in the prototype research phase, expected to have a prototype by the end of 2026 and enter animal clinical trials in 2027, collaborating with research institutions [2][9]. Strategic Partnerships - Aipeng Medical holds a stake in Ruishen An, a company focused on implantable neurostimulation devices, which has received 15 product certifications and is projected to exceed 100 million yuan in revenue by 2025, ranking among the top three to four in the domestic neurostimulation field [4][11]. Competitive Landscape - The company differentiates its strategy by focusing on pain, anesthesia, sleep, and attention disorders, contrasting with competitors that emphasize rehabilitation or motor imagery. Aipeng Medical plans to accumulate clinical validation through hospital channels before gradually promoting products to the consumer market [5][13]. - Non-invasive and semi-invasive brain-computer interface technologies each have their advantages. Non-invasive products are expected to commercialize rapidly within 2-3 years, while semi-invasive and fully implanted devices will become significant as technology advances and costs decrease [5][14]. Future Outlook - Aipeng Medical aims to enhance its stake in Ruishen An through share transfers, with expectations of results in the first half of the year, despite lengthy processes for state-owned capital exits [4][12]. - The company expects gradual recovery and stable growth in its pain management business by 2026, despite initial impacts from centralized procurement policies. The nasal care business faces challenges but is anticipated to rebound as the economy improves [15]. Additional Important Information - The company’s non-invasive products are currently not covered by medical insurance, which affects their market penetration and pricing strategy [7]. - Aipeng Medical's approach emphasizes building strong clinical data and partnerships with hospitals to establish a competitive edge in the medical field [14].

Core Insights - Boston Scientific has announced the acquisition of Valencia Technologies, focusing on bladder dysfunction treatment, particularly the eCoin® implantable tibial nerve stimulation (ITNS) system, marking its entry into a high-growth segment [2][6]. Technology Breakdown - The eCoin® system offers a novel physical intervention mechanism for treating urgency urinary incontinence (UUI), which is a symptom of overactive bladder (OAB). Traditional treatments often have significant side effects or poor adherence [4]. - Key features of the eCoin system include: - Coin-sized design with an integrated approach, eliminating the need for long wires [5]. - Minimally invasive implantation at the ankle, performed under local anesthesia in an office setting [5]. - Automated adjustment mechanism that stimulates the tibial nerve intermittently to modulate bladder control [5]. Clinical Validation - The eCoin system received FDA approval in 2022, targeting UUI patients who are intolerant or unresponsive to conservative treatments. A pivotal clinical trial showed a 68% response rate, with patients experiencing at least a 50% reduction in urinary incontinence episodes [6][10]. Strategic Rationale - Boston Scientific's acquisition of Valencia is seen as a strategic move to build a comprehensive neuromodulation matrix combining sacral nerve modulation (SNM) and ITNS, positioning itself in a high-growth adjacent market [6][9]. - The integration of eCoin into Boston Scientific's existing pelvic health sales channels is expected to facilitate rapid market penetration [8]. Competitive Landscape - The ITNS market is characterized by competition among key players, including Medtronic and Laborie. Boston Scientific's acquisition is a strategic response to strengthen its position against these competitors [9][12]. - The eCoin system's advantages include high patient adherence due to its automated operation and minimal invasiveness compared to traditional SNM procedures [11]. Financial Aspects - The financial details of the acquisition have not been disclosed, but Valencia had previously raised $35 million in funding, indicating a rising valuation [10]. - The transaction is expected to close in the first half of 2026, with minimal impact on Boston Scientific's adjusted EPS for that year, although some dilution may occur under GAAP [10]. Engineering Perspective - The success of the eCoin system is attributed to its ability to balance power and size, addressing engineering challenges in the development of implantable devices [14]. Conclusion - The acquisition of Valencia by Boston Scientific underscores a core strategy of expanding into disruptive technologies that are outpatient, minimally invasive, and user-friendly, thereby broadening treatment options for bladder dysfunction [14].

Group 1 - The core stock price of Beilu Pharmaceutical (300016) closed at 9.44 yuan on January 12, 2026, with an increase of 2.39% and a turnover rate of 8.34%, resulting in a trading volume of 469,100 shares and a transaction amount of 439 million yuan [1] - The company reported significant revenue growth from its export products, primarily contrast agents and raw materials, covering markets in South America, Africa, and Asia [2] - The overall gross margin for the company's overseas business in 2024 was only 17.57%, significantly lower than the disclosed gross margin of 49.2% for contrast agents, attributed to a higher proportion of raw materials in the export revenue structure [2] Group 2 - On January 12, the net inflow of main funds into Beilu Pharmaceutical was 7.25 million yuan, indicating positive engagement from major investors [3] - The net inflow of speculative funds was 4.87 million yuan, while retail investors experienced a net outflow of 12.12 million yuan [4]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is undergoing a period of accelerated transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each with its own advantages in signal quality, safety, and operational difficulty [5][19] - The Chinese brain-computer interface market is projected to grow significantly, with the market size reaching approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market [6] - The industry is supported by a three-pronged policy approach focusing on planning, payment, and standards, which is expected to facilitate rapid development [6][33] Summary by Sections 1. Brain-Computer Interface Overview - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to enable communication between the brain and external devices [17] - The technology operates through a closed-loop system involving signal input, processing, device control, and feedback [17] 2. Policy Support for BCI Development - The Chinese government has issued several policies to support the BCI industry, including the "Implementation Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry" which outlines goals for 2027 and 2030 [6][43] - The policies aim to establish a robust industrial ecosystem, enhance innovation capabilities, and promote clinical applications of BCI technologies [43][44] 3. Technological Advancements and Applications - Core technological breakthroughs are occurring in the upstream segment of the BCI industry, particularly in hardware such as electrodes and chips [7] - The medical application of BCI is predominant, with 56% of the market share in 2023, focusing on various therapeutic areas including cognitive disorders and movement disabilities [7][9] - Companies like Lepu Medical and Aipeng Medical are actively involved in developing deep brain stimulation (DBS) technologies, with some preparing for IPOs [7][8] 4. Investment Recommendations - The report suggests focusing on both invasive and non-invasive BCI products, with specific companies identified as beneficiaries based on their clinical trial progress and commercialization potential [8] - Notable companies include Aipeng Medical and Lepu Medical for invasive products, and Xiangyu Medical and Innovation Medical for non-invasive products [8]

Core Viewpoint - The article highlights the significant breakthrough achieved by Shenzhen Amygdala Neuro in the field of brain-computer interfaces (BCI) with the development of an endovascular electrode array that demonstrates long-term stability in large animal models, paving the way for clinical applications of BCI technology [2][12]. Group 1: Research Findings - The study successfully validated a mechanical architecture of an endovascular electrode array in large animal models, demonstrating nearly six months of dual-mode (recording + stimulation) functional stability [3][12]. - The research involved three adult sheep, where the electrode array was precisely implanted in the superior sagittal sinus, covering the motor cortex area, and monitored for nearly six months [4][12]. - Electrochemical impedance spectroscopy (EIS) measurements indicated good long-term electrochemical stability of the endovascular electrode in a vascular environment, with initial impedance around 1188 Ω, increasing to 2333 Ω by day 31, and then stabilizing at 1365 Ω by day 140 [6][12]. Group 2: Signal Recording and Stimulation - The study utilized the Apollo-I system to collect electrocorticography (ECoG) signals, revealing stable recordings of typical brain rhythms across various frequency bands (θ, α, β, low γ) [9][12]. - The stimulation results indicated that the threshold for eliciting body responses increased over time, with early responses at 1-2 mA (68% success rate) dropping to 3-5 mA (50% success rate) by day 112 [10][12]. - The electrode's ability to stimulate and record over a long duration supports the feasibility of using endovascular electrode arrays for neural modulation in clinical settings [11][12]. Group 3: Competitive Landscape - Synchron recently completed a $200 million Series D funding round, marking one of the largest single-round financings in the BCI field, which has drawn significant attention from the medical device industry [12]. - The article contrasts Amygdala Neuro's approach with Synchron's Stentrode™, highlighting the use of a mechanically woven nitinol stent and platinum-iridium microelectrodes, which offers advantages in terms of cost and flexibility for domestic BCI device development [12][13]. Group 4: Company Mission and Vision - Amygdala Neuro is committed to advancing brain-computer interface and neural modulation technologies, aiming to become a leading provider of solutions in neuroscience and high-reliability product manufacturing [16].